Total Payments
$542,542
2024 Payments
$53,458
Companies
49
Transactions
2,319
Medicare Patients
1,685
Medicare Billing
$546,037
Payment Breakdown by Category
Other$424,039 (78.2%)
Travel$69,336 (12.8%)
Food & Beverage$40,391 (7.4%)
Consulting$8,550 (1.6%)
Education$225.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $424,015 | 152 | 78.2% |
| Travel and Lodging | $69,336 | 165 | 12.8% |
| Food and Beverage | $40,391 | 1,986 | 7.4% |
| Consulting Fee | $8,550 | 5 | 1.6% |
| Education | $225.94 | 4 | 0.0% |
| Long term medical supply or device loan | $23.85 | 1 | 0.0% |
| Unspecified | $0 | 6 | 0.0% |
Payments by Type
General
$542,542
2,313 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals America, Inc. | $164,902 | 142 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $152,371 | 147 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $108,407 | 222 | $0 (2024) |
| ABBVIE INC. | $56,189 | 343 | $0 (2024) |
| Janssen Biotech, Inc. | $41,159 | 162 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,078 | 225 | $0 (2024) |
| Celgene Corporation | $3,021 | 291 | $0 (2024) |
| PFIZER INC. | $2,627 | 132 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $1,600 | 132 | $0 (2023) |
| Merck Sharp & Dohme LLC | $1,488 | 76 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,458 | 331 | ABBVIE INC. ($26,912) |
| 2023 | $32,130 | 302 | Janssen Biotech, Inc. ($14,543) |
| 2022 | $33,890 | 333 | ABBVIE INC. ($13,051) |
| 2021 | $29,899 | 248 | Janssen Scientific Affairs, LLC ($14,776) |
| 2020 | $15,019 | 187 | Janssen Scientific Affairs, LLC ($7,137) |
| 2019 | $71,542 | 283 | Janssen Scientific Affairs, LLC ($53,701) |
| 2018 | $98,400 | 291 | Takeda Pharmaceuticals U.S.A., Inc. ($67,295) |
| 2017 | $208,203 | 344 | Takeda Pharmaceuticals America, Inc. ($164,902) |
All Payment Transactions
2,319 individual payment records from CMS Open Payments — Page 1 of 93
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/20/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: GI | ||||||
| 12/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $1.35 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.89 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $27.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $1.81 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $1.78 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,325.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $27.70 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $33.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $32.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Gastroenterology | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $139.29 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $10.44 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $8.27 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $1.54 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/02/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $2.03 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 536 | 20,271 | $1.3M | $405,659 |
| 2022 | 12 | 454 | 615 | $408,325 | $54,027 |
| 2021 | 11 | 426 | 532 | $416,750 | $56,349 |
| 2020 | 10 | 269 | 346 | $186,790 | $30,002 |
Total Patients
1,685
Total Services
21,764
Medicare Billing
$546,037
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 12 | 19,500 | $783,120 | $338,142 | 43.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 130 | 218 | $81,750 | $16,255 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 129 | $51,600 | $14,229 | 27.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 40 | 41 | $86,100 | $9,080 | 10.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 47 | 48 | $98,400 | $6,082 | 6.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 31 | 31 | $54,250 | $5,060 | 9.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 43 | 44 | $79,200 | $4,244 | 5.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $16,000 | $4,146 | 25.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 45 | 45 | $20,250 | $3,807 | 18.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 13 | 64 | $19,200 | $3,667 | 19.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 18 | 18 | $6,250 | $685.26 | 11.0% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2023 | 16 | 19 | $950.00 | $219.30 | 23.1% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 17 | 82 | $4,100 | $41.83 | 1.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 146 | 237 | $88,875 | $18,863 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 69 | $27,600 | $7,483 | 27.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 45 | 45 | $92,250 | $6,137 | 6.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 24 | 25 | $52,500 | $6,000 | 11.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 38 | 38 | $68,400 | $3,762 | 5.5% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 22 | 22 | $38,500 | $3,743 | 9.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 28 | 28 | $12,600 | $2,692 | 21.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $9,500 | $2,630 | 27.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 31 | 31 | $10,850 | $1,833 | 16.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 11 | 11 | $2,750 | $592.10 | 21.5% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2022 | 15 | 19 | $950.00 | $253.06 | 26.6% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2022 | 15 | 71 | $3,550 | $37.40 | 1.1% |
About Dr. James George, MD
Dr. James George, MD is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659380244.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James George, MD has received a total of $542,542 in payments from pharmaceutical and medical device companies, with $53,458 received in 2024. These payments were reported across 2,319 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($424,015).
As a Medicare-enrolled provider, George has provided services to 1,685 Medicare beneficiaries, totaling 21,764 services with total Medicare billing of $546,037. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 08/05/2006
- Last Updated 05/24/2016
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1659380244
Products in Payments
- Entyvio (Biological) $244,664
- STELARA (Biological) $173,920
- RINVOQ (Biological) $25,488
- SKYRIZI (Biological) $24,363
- TREMFYA (Drug) $19,488
- ENTYVIO (Biological) $19,275
- ZEPOSIA (Drug) $3,021
- XIFAXAN (Drug) $2,453
- XELJANZ (Drug) $2,093
- DIFICID (Drug) $1,194
- Cimzia (Drug) $1,034
- HUMIRA (Biological) $1,014
- LINZESS (Drug) $915.15
- CLENPIQ (Drug) $802.24
- Humira (Biological) $608.09
- GATTEX (Drug) $570.59
- Sucraid (Drug) $559.29
- AVSOLA (Biological) $529.59
- INFLECTRA (Biological) $498.21
- NASCOBAL (Drug) $413.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554